A.C. PHARMA
ActiveSummary
The annual accounts of A.C. PHARMA for financial year 2025 show a net loss of 63% of the equity at the start of that year. The 2025 annual accounts show equity of €43,466 and a net result of -€74,212. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 27% of 12,661 sector peers (NACE 47, financial year 2025). The company has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 1.4% (low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
21-08
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 21 days late
2025
30-08
NBB filing
Annual accounts filed
financial year 2024 · full format · 30 days late
2024
31-12
Financial
Back to profitnet €34,622
Net result €34,622 after 2 loss-making years.
31-12
Financial
Equity above €100,000equity €117,678 ▲41.7%
Equity rises from €83,056 to €117,678.
19-11
NBB filing
Annual accounts filed
financial year 2023 · micro format · 111 days late
25-03
NBB filing
Annual accounts filed
financial year 2022 · micro format · 238 days late
24-01
Gazette deed
Resignation: CHELLAI Adil (manager)Appointments: CHELLAI Adil (director) and CHELLANI Farid (alternate director) · Permanent representative: CHELLAI Adil · Legal-form conversion11 facts ▸
Gazette deed
Resignation: CHELLAI Adil (manager)
Appointments: CHELLAI Adil (director) and CHELLANI Farid (alternate director) · Permanent representative: CHELLAI Adil · Legal-form conversion11 facts ▸
- General meeting, 23-12-2023
- Other provision, “statuts antérieurs” (deed in French)
- Legal-form conversion, “société à responsabilité limitée” (deed in French)
- Capital conversion, “fonds disponibles pour distribution” (deed in French)
- Amendment of the articles
- Capital
- Director resignation, CHELLAI Adil (manager)
- Director appointment, CHELLAI Adil (director (not named in the articles))
- Permanent representative, CHELLAI Adil (représentant permanent de la société)
- Director appointment, CHELLANI Farid (alternate director)
- Power of attorney, Pierre LEBON
2023
31-12
Financial
Weakest financial yearnet -€238,137
Net result drops to -€238,137, the lowest in the series; recovery starts the following year.
17-08
NBB filing
Annual accounts filed
financial year 2021 · micro format · 382 days late
2022
31-12
Financial
Liquidity more than doubledcurrent ratio 3.60
Current ratio from 1.64 to 3.60; short-term debt falls from €631,253 to €151,368.
29-07
NBB filing
Annual accounts filed
financial year 2020 · micro format · 363 days late
2021
31-12
Financial
Highest result from 2018 to 2025net €212,105 ▲70%
Operating result €219,008, net result €212,105, both a record.
Show earlier events
31-12
Financial
Equity above €200,000equity €328,157 ▲183%
2 profitable years in a row build equity to €328,157.
2020
31-12
Financial
Back to profitnet €124,795
Net result €124,795 after one loss-making year.
31-12
Financial
Equity above €100,000equity €116,052 ▲45,188%
Equity rises from €256 to €116,052.
11-12
NBB filing
Annual accounts filed
financial year 2019 · full format · 133 days late
27-01
NBB filing
Annual accounts filed
financial year 2018 · full format · 180 days late
2019
02-08
NBB filing
Annual accounts filed
financial year 2017 · full format · 367 days late
2017
17-08
NBB filing
Annual accounts filed
financial year 2016 · full format · 17 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
1 of 3 deeds read
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.